WO2001016162A1 - Verfahren zur herstellung von zyklischen peptidomimetika - Google Patents
Verfahren zur herstellung von zyklischen peptidomimetika Download PDFInfo
- Publication number
- WO2001016162A1 WO2001016162A1 PCT/DE2000/002982 DE0002982W WO0116162A1 WO 2001016162 A1 WO2001016162 A1 WO 2001016162A1 DE 0002982 W DE0002982 W DE 0002982W WO 0116162 A1 WO0116162 A1 WO 0116162A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- peptidomimetic
- nucleophilic
- cyclization
- functionality
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- peptides are limited for the following reasons: (i) Under physiological conditions, peptides are degraded by many specific and non-specific peptidases, (ii) peptides are only moderately absorbed and quickly excreted again. (iii) The conformational flexibility of peptides can lead to binding to more than one receptor and thus to undesirable side effects, (iv) peptides can be immunogenic.
- the resulting conformationally restricted peptide analogs can not only lead to increased avidity and affinity for the receptor [Ladner, CL TIBTECH 1995, 13, 426] but also have a significantly reduced lability towards proteases and a significantly increased membrane passage [Hruby, VJ et al. Life Be. 1982, 31, 189].
- the object is to produce peptides or peptidomimetics which no longer have the aforementioned disadvantageous properties of peptides for clinical applications.
- cyclic peptides and peptidomimetics are to be synthesized, the backbone of which is modified by aromatic or heteroaromatic residues.
- the object is achieved by a process for the synthesis of cyclic peptides or peptidomimetics by sequential nucleophilic substitutions on polyhalogenated aromatics with the following formula: (i) 2,4,6-trihalo-S-triazine or 2,4,6-trihalo-1 , 3,5-triazine; (see.
- a linear peptide or peptidomimetic with a free nucleophilic functionality wherein the nucleophilic functionality is an alcohol, thiol or amine, and wherein the nucleophilic functionality is either at one end, in the side chain or on the backbone of the peptide or peptidomimetic implemented with the aromatic in the sense of a simple nucleophilic aromatic substitution, the peptide or peptidomimetic being in solution or in a state bound to a solid phase
- the protective group of a further nucleophilic functionality on the same peptide or peptidomimetic is selectively cleaved, the nucleophilic functionality released being an alcohol, thiol or amine, and the nucleophilic functionality being at either end in which
- the present method is a valuable tool for the synthesis of new bioactive compounds.
- the following invention describes a new, versatile procedure for the production of such, not previously described, conformationally restricted connections.
- a process according to the invention is preferred, the polyhalogenated aromatic being a cyanuric chloride or fluoride.
- a cyanuric chloride is more preferred.
- a method according to the invention is advantageous in which the remaining halogen atoms are reacted in further nucleophilic aromatic substitution reactions, the nucleophile being an alcohol, a thiol or an amine.
- the nucleophile can be part of the same peptide or peptidomimetic or part of another molecule. This creates intramolecular or intermolecularly linked compounds.
- the present invention relates to a process for the preparation of novel cyclic peptidomimetics by means of successive nucleophilic substitution on cyanuric chloride and other polyhalogenated aromatic compounds.
- peptides or peptidomimetic oligomers which are built up by means of solid-phase or solution synthesis and initially have only one free nucleophilic functional group are reacted with cyanuric chloride.
- cyanuric chloride The temperature-dependent tendency of substitution of the chlorine atoms present is exploited [Thurston, JT et al. J. Am. Chem. Soc. 1951, 73, 2981].
- the complete reaction of amino, hydroxy, or thiol functions with excess cyanuric chloride at room temperature initially leads exclusively to dichloro-1, 3,5-triazinylpeptides (Scheme II) without the formation of 1,3,5-triazine-bridged peptide dimers.
- the method according to the invention makes a large variety of conformationally restricted compounds accessible.
- both the ring size and the molecular weight can be gradually changed.
- Figure 1 shows possible ring closure reactions in peptides and peptidomimetics.
- Figure 2 shows the schematic representation of the production of cyclic peptidomimetics by means of sequential aromatic substitution using the example of
- Figure 3 shows a solid phase cyclization using cyanuric chloride to cycles of different ring sizes and molecular weights.
- FIG. 4 shows the increase in the diversity of the cyclized compounds by nucleophilic substitution of the remaining chlorine atom on the ring system.
- FIG. 5 shows the cyclization of dipeptides by means of cyanuric chloride in FIG.
- FIG. 6 shows the representation of the solid phase cyclization of dipeptides in FIG.
- FIG. 7 shows the “head to backbone” cyclization on peptomers.
- FIG. 8 shows the representation of the nucleophilic substitution on cyclic monochloro-1,3,5-triazinylpeptides.
- FIG. 9 shows a “head-to-tail” cyclization in solution.
- FIG. 10 shows the aromatics of the process according to the invention, a chlorine atom being used as an example for the halogen.
- the chlorine atom is to be replaced by halogen in the general formulas.
- All peptides and peptidomimetics can optionally include protecting groups.
- the protective group at the N terminus can consist of: alkyl, aryl, alkylaryl, arylalkyl, alkylcarbonyl, arylcarbonyl, alkylsulfonyl,
- Carbon atoms preferably fluorenylmethoxycarbonyl, tert. butyloxycarbonyl,
- the protecting group C - terminus can consist of: An alkoxy or aryloxy group with 1 to 10 carbon atoms or one
- Peptide In the context of the present application, the term “peptide” also includes peptide derivatives and analogs which contain at least one peptide bond.
- Oligo-N-alkyl-glycine in which formally the side chains of the peptides are transferred from the ⁇ -carbon atom of the amino acids to the amide function.
- the side chain protecting groups were cleaved for 2.5 hours with a solution of 5% water, 5% phenol, 2.5% triisopropylsilane in TFA.
- the orthogonal lysine protecting group (Mtt) could be cleaved in 1h using a solution of 1% TFA and 5% triisopropylsilane in DCM without affecting the other acid labile protecting groups.
- Example 3 Studies on the solid phase cyclization of dipeptides using cyanuric chloride
- the diverse application possibilities of the new method can be expanded if the cyclization is transferred to peptide-related oligomers.
- the synthesis of peptomers (hybrids of peptides and peptoids) or peptoids, which leads to N-alkylated compounds also opens up the possibility of carrying out cyclizations on the backbone of the peptidomimetic (see scheme I) [Gilon, C. et al. Biopolymers 1991, 31, 745].
- the peptomers shown in Figure 6 were synthesized. For this purpose, as described in the general synthesis strategy, the cellulose membrane was first modified with the photolinker.
- the BOC protecting groups of the amino functions of the peptoid building blocks could be removed by bathing the membrane for 30 minutes in a solution of 5% water in 90% TFA / DCM. After washing again, the cyclization with 30% DIEA in DMF at room temperature was achieved within 30 minutes. After washing the membrane (5xDMF, 3xMeOH, 1xDCM) and drying, the cyclized compounds were cleaved from the cellulose surface by UV irradiation at 365 nm (120 min). LC-MS analysis of the compounds showed that the desired product was obtained in all cases.
- Example 5 Studies on the substitution of the chlorine atom on cyclic monochloro-1, 3,5-triazinyl peptides bound to the solid phase.
- Example 6 Testing of different multi-halogenated azaaromatic compounds for solid phase cycling
- the linear tripeptide AFK was synthesized as described in Example 1.
- the excess of reagent was removed by washing with DMF, methanol and DCM (3 ⁇ 5 min each).
- the membrane (5xDMF, 3xMeOH, 1xDCM)
- the BOC protecting group of the ⁇ -amino function was removed from the lysine by bathing the membrane in a solution of 5% water in 90% TFA / DCM for 30 minutes.
- Termini are anchored to the carrier, a "head to tail" cyclization must be carried out in solution.
- the following example describes such a ring closure on one
- the dichloro-triazine derivative thus obtained was cleaved from the membrane with 80% TFA in DCM for 30 min at RT (FIG. 9, compound 1).
- the excess TFA and DCM were removed in vacuo and taken up in 50 ul of a 50% solution of acetonitrile in water. 10 ⁇ l of these were analyzed by LC-MS.
- the cyclization was achieved by adding 2 ⁇ l DIEA and shaking at RT for 30 min (FIG. 9, compound 2).
- the mixture was then evaporated to dryness again in vacuo and taken up in 50 ⁇ l of a 50% strength solution of acetonitrile in water and the reaction product was analyzed by means of LC-MS.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001519723A JP2003508408A (ja) | 1999-08-28 | 2000-08-28 | 環状偽ペプチッドの製造方法 |
EP00963949A EP1212351A1 (de) | 1999-08-28 | 2000-08-28 | Verfahren zur herstellung von zyklischen peptidomimetika |
AU75061/00A AU7506100A (en) | 1999-08-28 | 2000-08-28 | Method for producing cyclic peptidomimetics |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19942624.4 | 1999-08-28 | ||
DE19942624A DE19942624A1 (de) | 1999-08-28 | 1999-08-28 | Verfahren zur Herstellung von zyklischen Peptidomimetika |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001016162A1 true WO2001016162A1 (de) | 2001-03-08 |
Family
ID=7921062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2000/002982 WO2001016162A1 (de) | 1999-08-28 | 2000-08-28 | Verfahren zur herstellung von zyklischen peptidomimetika |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1212351A1 (de) |
JP (1) | JP2003508408A (de) |
AU (1) | AU7506100A (de) |
DE (1) | DE19942624A1 (de) |
WO (1) | WO2001016162A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005059180A1 (en) * | 2003-12-17 | 2005-06-30 | Illumina, Inc. | Methods of attaching oligonucleotides and peptides to solid supports using 2,4-hydrazin- (1, 3, 5) triazine-activated solid phases |
US9181298B2 (en) | 2003-06-18 | 2015-11-10 | Ocera Therapeutics, Inc. | Intermediates for macrocyclic compounds |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013100132A1 (ja) | 2011-12-28 | 2013-07-04 | 中外製薬株式会社 | ペプチド化合物の環化方法 |
DK3269809T3 (da) | 2015-03-13 | 2022-09-12 | Chugai Pharmaceutical Co Ltd | MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF |
KR102610527B1 (ko) | 2017-06-09 | 2023-12-05 | 추가이 세이야쿠 가부시키가이샤 | N-치환 아미노산을 포함하는 펩타이드의 합성 방법 |
US11492369B2 (en) | 2017-12-15 | 2022-11-08 | Chugai Seiyaku Kabushiki Kaisha | Method for producing peptide, and method for processing bases |
US11732002B2 (en) | 2018-11-30 | 2023-08-22 | Chugai Seiyaku Kabushiki Kaisha | Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990002750A1 (fr) * | 1988-09-02 | 1990-03-22 | Centre National De La Recherche Scientifique (Cnrs) | Derives de cyclopeptides, utilisables comme inhibiteurs selectifs, vis-a-vis de proteases a serine active |
WO1997010263A1 (en) * | 1995-09-12 | 1997-03-20 | Auda Pharmaceuticals Aps | Actinomycin d analogues |
US5656645A (en) * | 1994-12-13 | 1997-08-12 | Corvas International, Inc. | Aromatic heterocyclic derivatives as enzyme inhibitors |
WO1997039024A1 (en) * | 1995-04-25 | 1997-10-23 | The University Of Kansas | Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability |
-
1999
- 1999-08-28 DE DE19942624A patent/DE19942624A1/de not_active Withdrawn
-
2000
- 2000-08-28 WO PCT/DE2000/002982 patent/WO2001016162A1/de not_active Application Discontinuation
- 2000-08-28 EP EP00963949A patent/EP1212351A1/de not_active Withdrawn
- 2000-08-28 JP JP2001519723A patent/JP2003508408A/ja active Pending
- 2000-08-28 AU AU75061/00A patent/AU7506100A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990002750A1 (fr) * | 1988-09-02 | 1990-03-22 | Centre National De La Recherche Scientifique (Cnrs) | Derives de cyclopeptides, utilisables comme inhibiteurs selectifs, vis-a-vis de proteases a serine active |
US5656645A (en) * | 1994-12-13 | 1997-08-12 | Corvas International, Inc. | Aromatic heterocyclic derivatives as enzyme inhibitors |
WO1997039024A1 (en) * | 1995-04-25 | 1997-10-23 | The University Of Kansas | Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability |
WO1997010263A1 (en) * | 1995-09-12 | 1997-03-20 | Auda Pharmaceuticals Aps | Actinomycin d analogues |
Non-Patent Citations (3)
Title |
---|
HAUBNER, ROLAND ET AL.: "CYCLIC RGD PEPTIDES CONTAINING BETA -TURN MIMETICS", J AM CHEM SOC (1996) 118(34) 7881-7891, XP002158161 * |
HERBERT C G ET AL: "PREPARATION OF POLY(ARYLENE ETHER PYRIMIDINE)S BY AROMATIC NUCLEOPHILIC SUBSTITUTION REACTIONS", MACROMOLECULES,US,AMERICAN CHEMICAL SOCIETY. EASTON, vol. 29, no. 24, 18 November 1996 (1996-11-18), pages 7709 - 7716, XP000631121, ISSN: 0024-9297 * |
RANGANATHAN, DARSHAN ET AL.: "CYSTINOPHANES A NOVEL FAMILY OF AROMATIC -BRIDGED CYSTINE CYCLIC PEPTIDES SYNTHESIS CRYSTAL STRUCTURE MOLECULAR RECOGNITION AND CONFORMATIONAL STUDIES", J AM CHEM SOC (1998) 120(12) 2695-2702, XP002158160 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9181298B2 (en) | 2003-06-18 | 2015-11-10 | Ocera Therapeutics, Inc. | Intermediates for macrocyclic compounds |
US10040751B2 (en) | 2003-06-18 | 2018-08-07 | Ocera Therapeutics, Inc. | Intermediates for macrocyclic compounds |
WO2005059180A1 (en) * | 2003-12-17 | 2005-06-30 | Illumina, Inc. | Methods of attaching oligonucleotides and peptides to solid supports using 2,4-hydrazin- (1, 3, 5) triazine-activated solid phases |
US7259258B2 (en) | 2003-12-17 | 2007-08-21 | Illumina, Inc. | Methods of attaching biological compounds to solid supports using triazine |
US7504499B2 (en) | 2003-12-17 | 2009-03-17 | Illumina, Inc. | Methods of attaching biological compounds to solid supports using triazine |
US7863058B2 (en) | 2003-12-17 | 2011-01-04 | Illumina, Inc. | Methods of attaching biological compounds to solid supports using triazine |
US7977476B2 (en) | 2003-12-17 | 2011-07-12 | Illumina, Inc. | Methods of attaching biological compounds to solid supports using triazine |
US8207332B2 (en) | 2003-12-17 | 2012-06-26 | Illumina, Inc. | Methods of attaching biological compounds to solid supports using triazine |
Also Published As
Publication number | Publication date |
---|---|
AU7506100A (en) | 2001-03-26 |
EP1212351A1 (de) | 2002-06-12 |
DE19942624A1 (de) | 2001-03-08 |
JP2003508408A (ja) | 2003-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0285562B1 (de) | Kunstharz | |
DE69435011T2 (de) | Selektiv spaltbare Linker, die auf einer Methionin- und einer Estergruppe basieren | |
DE69936322T2 (de) | Polyamideketten von genauer Länge und deren Konjugate mit Proteinen | |
DE60208684T2 (de) | Verbesserte native chemische ligation mit drei oder mehreren komponenten | |
EP0906918B1 (de) | Verfahren zur Gewinnung von Insulinvorläufern mit korrekt verbundenen Cystinbrücken | |
Romanovskis et al. | Preparation of head‐to‐tail cyclic peptides via side‐chain attachment: implications for library synthesis | |
US7691968B2 (en) | Process for the synthesis of peptides amides by side-chain attachment to a solid phase | |
CA1188297A (en) | Methods and compositions for preparation of h-arg-x-z- y-tyr-r | |
WO2001016162A1 (de) | Verfahren zur herstellung von zyklischen peptidomimetika | |
DE69915160T2 (de) | Verfahren zur Herstellung des Somatostatin Analogons Octreotide | |
DE4119544C1 (de) | ||
DE60124376T2 (de) | Funktionalisierter festträger zur organischen synthese von peptiden und kleinen molekülen | |
EP0051205B1 (de) | Neues Tridekapeptid, Verfahren zu seiner Herstellung und Verwendung | |
DE60026708T2 (de) | Verfahren zur entschützung von geschützten thiolen | |
CN107383054B (zh) | 一种含二硫键长臂生物素及其制备方法 | |
ES2307039T3 (es) | Preparacion de los peptidos de la somatostatina. | |
US6277958B1 (en) | Method for preparing peptide thiol ester | |
Arai et al. | Synthesis of (Hexafluorovalyl1, 1) gramicidin S. | |
HU185238B (en) | Process for preparing peptides containing guanidino-group | |
HU221619B1 (hu) | Eljárás peptidek előállítására és intermedierek | |
DE2327396A1 (de) | Synthetisches polypeptid und verfahren zur herstellung desselben | |
EP1373190A2 (de) | Verfahren zur herstellung von carbonsäureamiden | |
EP0443598B1 (de) | Die Blutgerinnung inhibierende Peptide, Verfahren zu ihrer Herstellung und ihre Verwendung | |
DE60032759T2 (de) | Funktionalisierte festträger zur herstellung von alpha-oxoaldehyden | |
DE3417413A1 (de) | Dicarbonsaeure-monohydrazid-derivate, ihre herstellung und ihre verwendung als kopplungskomponenten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WD | Withdrawal of designations after international publication |
Free format text: DE |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 519723 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000963949 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000963949 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000963949 Country of ref document: EP |